The current price-to-earnings ratio of NEO can't be determined, as the TTM EPS of -$0.66 is negative. Neogenomics's last PE ratio on record was 114.86 in September 2021.
The mean historical PE ratio of Neogenomics over the last ten years is 653.49. In the past ten years, NEO's PE ratio reached its highest point in the Jun 2019 quarter at 2,194, with a price of $21.94 and an EPS of $0.01. The Jun 2021 quarter saw the lowest point at 74.05, with a price of $45.17 and an EPS of $0.61.
Maximum annual increase: 268.13% in 2020
| Year | PE ratio | Change |
|---|---|---|
| 2023 | N/A | N/A |
| 2022 | N/A | N/A |
| 2021 | N/A | N/A |
| 2020 | 1,346 | 268.13% |
| 2019 | 365.63 | 102.97% |
| 2018 | 180.14 | N/A |
| 2017 | N/A | N/A |
| 2016 | N/A | N/A |
| 2015 | N/A | N/A |
| 2014 | 208.5 | 130.39% |
| Stock name | PE ratio | Market cap |
|---|---|---|
| ENZ Enzo Biochem Inc | 1.25 | $59.18M |
| DGX Quest Diagnostics Inc | 19.41 | $16.21B |
| LH Laboratory Corp Of America Holdings | 41.35 | $17.78B |
| RDNT RadNet Inc | 187.82 | $4.58B |
| NEO Neogenomics Inc | N/A | $1.9B |
The current price to earnings ratio of NEO can't be calculated, as its EPS of -$0.66 is negative.
The 5-year average PE ratio for NEO stock is 788.81.
In the last ten years, the Jun 2019 quarter recorded the highest quarterly PE ratio at 2,194.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.